Jie Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie Gao has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Lunquan Sun
27 shared publications- Xiaoyu Liu
Department of Radiology and Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
27 shared publications - Xu Xu
College of Chemistry, Liaoning University, Shenyang, 110036, China
27 shared publications - Yuefang Zhang
State Key Laboratory of Neuroscience, Institute of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China
27 shared publications - Yuezhen Deng
Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
27 shared publications - Zhi Li
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
27 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-13
Six-Transmembrane Epithelial Antigen of the Prostate 1 Promotes HCC Proliferation and Metastasis in vitro and in vivo via the Wnt/β-Catenin Signaling Pathway
To investigate the role and underlying mechanism of Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) in Hepatocellular carcinoma (HCC) progression, and to validate its potential as a therapeutic target. In this study, STEAP1-knockdown models were used to evaluate cell proliferation, invasion and migration. RNA sequencing (RNA-seq) were performed to explore downstream mechanisms. Subcutaneous Xenograft Model in nude mice was used to investigate the role of STEAP1 in the proliferation of HCC in vivo. STEAP1 knockdown significantly inhibited HCC cell proliferation, invasion, and migration, downregulated the expression of EMT-related proteins, and suppressed activation of the Wnt signaling pathway. In vivo, STEAP1 silencing effectively reduced the growth of subcutaneous tumors in nude mice. STEAP1 promotes HCC growth and metastasis by activating the Wnt/β-catenin signaling pathway, and may serve as a promising therapeutic target for HCC.
- 1 January 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-13
Open AccessSix-Transmembrane Epithelial Antigen of the Prostate 1 Promotes HCC Proliferation and Metastasis in vitro and in vivo via the Wnt/β-Catenin Signaling Pathway
To investigate the role and underlying mechanism of Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) in Hepatocellular carcinoma (HCC) progression, and to validate its potential as a therapeutic target. In this study, STEAP1-knockdown models were used to evaluate cell proliferation, invasion and migration. RNA sequencing (RNA-seq) were performed to explore downstream mechanisms. Subcutaneous Xenograft Model in nude mice was used to investigate the role of STEAP1 in the proliferation of HCC in vivo. STEAP1 knockdown significantly inhibited HCC cell proliferation, invasion, and migration, downregulated the expression of EMT-related proteins, and suppressed activation of the Wnt signaling pathway. In vivo, STEAP1 silencing effectively reduced the growth of subcutaneous tumors in nude mice. STEAP1 promotes HCC growth and metastasis by activating the Wnt/β-catenin signaling pathway, and may serve as a promising therapeutic target for HCC.
- 24 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (2) , e70349
Betaine‐homocysteine methyltransferase attenuates liver ischemia–reperfusion injury by targeting TAK1
Liver ischemia–reperfusion (IR) injury is a common complication following liver surgery, significantly impacting the prognosis of liver transplantation and other liver surgeries. Betaine‐homocysteine methyltransferase (BHMT), a crucial enzyme in the methionine cycle, has been previously confirmed the pivotal role in hepatocellular carcinoma, and it has also been demonstrated that BHMT inhibits inflammation, apoptosis, but its role in liver IR injury remains unknow. Following I/R injury, we found that BHMT expression was significantly upregulated in human liver transplant specimens, mice and hepatocytes. Utilizing BHMT knockout mice, we established an in vivo model of liver IR injury, and with BHMT knockout and overexpression AML12 cell lines, we created an in vitro hypoxia–reoxygenation model. Our findings reveal that BHMT deficiency exacerbates liver IR injury, leading to increased reactive oxygen species, apoptosis and inflammation, whereas BHMT overexpression mitigates these effects. We observed that BHMT inhibits the c‐Jun N‐terminal kinase (JNK)/p38 signaling pathway in liver IR injury by interacting with TAK1 and inhibiting its activity. The application of 5z‐7‐ox, a TAK1 inhibitor, reversed the worsening of liver IR injury and the activation of the JNK/p38 pathway associated with BHMT deficiency. These results demonstrate that BHMT protects against liver IR injury by targeting TAK1 and inhibiting the JNK/p38 signaling pathway. Our findings suggest that BHMT may be a promising therapeutic target for preventing liver IR injury.
- 24 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (2) , e70349
Betaine‐homocysteine methyltransferase attenuates liver ischemia–reperfusion injury by targeting TAK1
Liver ischemia–reperfusion (IR) injury is a common complication following liver surgery, significantly impacting the prognosis of liver transplantation and other liver surgeries. Betaine‐homocysteine methyltransferase (BHMT), a crucial enzyme in the methionine cycle, has been previously confirmed the pivotal role in hepatocellular carcinoma, and it has also been demonstrated that BHMT inhibits inflammation, apoptosis, but its role in liver IR injury remains unknow. Following I/R injury, we found that BHMT expression was significantly upregulated in human liver transplant specimens, mice and hepatocytes. Utilizing BHMT knockout mice, we established an in vivo model of liver IR injury, and with BHMT knockout and overexpression AML12 cell lines, we created an in vitro hypoxia–reoxygenation model. Our findings reveal that BHMT deficiency exacerbates liver IR injury, leading to increased reactive oxygen species, apoptosis and inflammation, whereas BHMT overexpression mitigates these effects. We observed that BHMT inhibits the c‐Jun N‐terminal kinase (JNK)/p38 signaling pathway in liver IR injury by interacting with TAK1 and inhibiting its activity. The application of 5z‐7‐ox, a TAK1 inhibitor, reversed the worsening of liver IR injury and the activation of the JNK/p38 pathway associated with BHMT deficiency. These results demonstrate that BHMT protects against liver IR injury by targeting TAK1 and inhibiting the JNK/p38 signaling pathway. Our findings suggest that BHMT may be a promising therapeutic target for preventing liver IR injury.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 1 The primer sequences for qPCR and shRNA.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 1 The primer sequences for qPCR and shRNA.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 3 The BIOCYC analysis for the kinase candidates.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 3 The BIOCYC analysis for the kinase candidates.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 4 Correlation between the mRNA level of NME7 and the clinical features of HCC.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 4 Correlation between the mRNA level of NME7 and the clinical features of HCC.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 2 The KEGG analysis for the kinase candidates.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 2 The KEGG analysis for the kinase candidates.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 2 The KEGG analysis for the kinase candidates.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 2 The KEGG analysis for the kinase candidates.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Materials and Methods and Supplemental Figures and Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Materials and Methods and Supplemental Figures and Legends
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 3 The BIOCYC analysis for the kinase candidates.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Table 3 The BIOCYC analysis for the kinase candidates.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Materials and Methods and Supplemental Figures and Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma
Supplemental Materials and Methods and Supplemental Figures and Legends